Sign in
Taking people in United StatesNo phase

MaioRegen Prime implant versus surgical cleaning for deep knee cartilage and bone damage

Compares a scaffold implant with debridement in adults with deep knee osteochondral lesions.

Key facts

Who runs it
Fin-Ceramica Faenza Spa
Where
Ann Arbor, Cincinnati, Columbus, Jackson, La Mesa, Oak Brook, Portland, Rockwall, and Steamboat Springs, United StatesSee the 9 sitesAlso in 1 other country, 1 site
Trial code
Registry title
MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee
Status
Recruiting
People taking part
400 people, planned
Started
Sept 2026
Expected to end
30 Apr 2031
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • osteochondral scaffold implant
  • SSOC
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with deep damage to the cartilage and bone of the knee who did not improve with physical therapy. It compares the MaioRegen Prime implant with debridement (surgical cleaning of the damaged area).

Age
18 to 60 years
Sex
All sexes
Disease stage
Up to 3 knee lesions on the thigh bone end (femoral condyles) and/or trochlea, ICRS Grade IVa or IVb, or Osteochondritis Dissecans lesions that cannot be fixed back. Total area 1-7 cm2 on MRI. IKDC Subjective score less than 70. BMI ≤ 35.
Earlier treatment
No improvement after physical therapy for at least 6 weeks. No cartilage repair procedure in this knee within one year, and no debridement within 6 months. No steroid injections into the joint within 3 months. No chemotherapy in the past 12 months.

Main reasons for not taking part

  • Advanced knee osteoarthritis (Kellgren and Lawrence 3 or 4), or lesions on the tibial plateau or kneecap
  • Bone defect deeper than 5 mm, or knee instability or misalignment that has not been treated
  • Earlier removal of more than 50% of the meniscus in the affected part of the knee
  • Osteoporosis, allergy to equine collagen or calcium-phosphates, or serious systemic disease such as HIV or hepatitis
  • Pregnancy, planning pregnancy within one year after surgery, or breastfeeding

The registry criteria, word for word

Show all 39 criteriaShow less

Who can take part

  • Informed consent prior to any study-related procedures
  • Male or female patients aged between 18 and 60 years (inclusive)
  • Body Mass Index (BMI) ≤ 35
  • Up to 3 treatable osteochondral lesions localized in femoral condyles and/or trochlea (the patient might have other lesion in other parts of the joint, but they should not be more severe than ICRS Grade II lesions as determined by baseline MRI)
  • Knee osteochondral lesion(s) (Grade IVa and IVb according to ICRS Classification) or not re-fixable knee Osteochondritis Dissecans lesions as determined by baseline MRI
  • Lesions with an overall treatable area 1-7 cm2 (as determined by baseline MRI). In case of multiple lesions (maximum 3 lesions) in the same knee compartment a minimum distance of 3 mm is required)
  • IKDC Subjective score at baseline (pre-op evaluation) is less than 70
  • Non-responsive to physical therapy for at least 6 weeks
  • Patients physically and mentally willing and able to comply with the post-operative rehabilitation protocol and scheduled clinical and radiographic visits

Who cannot take part

  • Patients previously treated for total or partial meniscectomy in the specific index knee compartments (more than 50% of the meniscus in the index compartments is missing)
  • Patients affected by any concomitant painful or disabling disease of the spine, hips, or lower limbs, including the contralateral knee, that would interfere with the evaluation of the index knee
  • Intra-articular steroid injections within 3 months
  • Any previous cartilage repair procedure (such as: microfracture, Osteochondral autograft transplantation system (OATS), Autologous Matrix Induced Chondrogenesis, (AMIC), Autologous Chondrocyte Implantation (ACI) with or without use of a scaffold (matrix) in the index knee within one year or debridement within 6 months
  • Patients who underwent chemotherapy in the past 12 months
  • Participation in other clinical trials within 90 days prior to the study or concurrent with the study
  • Known drugs or alcohol abuse
  • Patients with a known history of any significant systemic disease (such as but not limited to: HIV, hepatitis, HTLV, syphilis, coagulopathies, insulin dependent diabetes mellitus etc.) or affected by a significant malignancy
  • Any evidence of active infection anywhere in the body. Urinary Tract Infection (UTI) patients can be included following antibiotic treatment, and provided that two consecutive cultures are negative (taken within at least 2 weeks of each other)
  • Any known history of intra-articular or osseous infection of the index knee
  • Patients affected by a known history of inflammatory arthropathy or crystal-deposition arthropathy
  • The existence of any surgical or medical condition that, in the judgement of the Investigator, might compromise patient safety or the outcome of the study
  • Any medical conditions or implants that would prevent the participant from undergoing an MRI, including but not limited to pacemakers, clips, cochlear implants, or metal shrapnel
  • Patients affected by known allergy to equine collagen or calcium-phosphates
  • IKDC subjective score at Baseline is more than or equal to 70
  • KOOS Pain Subscale score at baseline is less than 20 or more than 65 (scale: maximum pain = 0, pain free = 100)
  • Osteochondral tibial plateau and/or patella defects
  • Patients affected by advanced osteoarthritis in the index knee (Kellgren and Lawrence classification 3 or 4)
  • Bony defect depth deeper than 5 mm, according to baseline MRI, measured from the original subchondral bone plate level
  • Uncontained defects: lack of vital bone wall at least 2 mm thick, completely surrounding the lesion - based on MRI
  • Patients with untreated patellofemoral malalignment or who have undergone realignment procedures within 6 months
  • Patients with bone fracture or uncorrected malalignment more than 5 degrees varus or valgus according to standing X-ray
  • Patient requiring total or partial meniscectomy to be performed concomitantly, involving more than 50% of one or both menisci in the index knee compartment (lack of functional remaining meniscus, at least 5mm rim at the end of the procedure); and patient requiring ligamentoplasty and high tibial osteotomy (HTO) to be performed concomitantly
  • Untreated knee ligament instability or treated within 6 months
  • Kissing (counterposed) osteochondral lesions
  • Significant instability of the index knee according to IKDC Knee Examination Form 2000: Grade C (abnormal) or D (severely abnormal)
  • Patients affected by bilateral knee lesions that need treatment
  • Patients affected by osteoporosis (established through x-ray tests, called DEXA scans, bone density, etc. Criteria for osteoporosis: T-score is < - 2.5 SD), chondrodysplasia, or osteogenesis imperfecta
  • Patient who is pregnant (or intends to become pregnant within one-year post-op) or breastfeeding
  • Prisoners

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Where in United States

Also in 1 other country, 1 site

  • University of Michigan Med schoolAnn Arbor, United StatesContact: John Grant (principal investigator)Taking people
  • University of Cincinnati Medical CenterCincinnati, United StatesContact: Brian Grawe (principal investigator)Taking people
  • Ohio State UniversityColumbus, United StatesContact: David Flanigan (principal investigator)Taking people
  • Clinical Research SolutionsJackson, United StatesContact: Jason Hutchison (principal investigator)Taking people
  • Grossmont Orthopaedic Medical GroupLa Mesa, United StatesContact: Scott Hacker (principal investigator)Not yet recruiting
  • Genesis Orthopedics & Sports MedicineOak Brook, United StatesContact: Hythem Shadid (principal investigator)Taking people
  • Oregon Health & Science University in PortlandPortland, United StatesContact: Dennis Charles Crawford (principal investigator)Taking people
  • North Texas Medical Research InstituteRockwall, United StatesContact: Mohammad Umar Burney (principal investigator)Taking people
  • Steamboat Orthopaedic & Spine InstituteSteamboat Springs, United StatesContact: Alexander Meininger (principal investigator)Taking people

About the trial

What the trial wants to find out

The present study aims to compare the efficacy and the safety of MaioRegen Prime to Debridement (SSOC) in patients with deep osteochondral lesions of the knee joint. The foreseen population involves patients with osteochondral lesions with different etiology, dimension, shape, and location.

Read full original descriptionShow less

The evaluation will be performed through clinical, subjective and objective assessments.

The 2 groups in the trial

  • MaioRegen PrimeTreatment being tested

    Medical Device: MaioRegen Prime implant

    Treatment: osteochondral scaffold implant

  • Surgical Standard of Care (SSOC)Existing treatment, for comparison

    Debridement

    Treatment: SSOC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Multicenter Prospective Randomized Study of MaioRegenTM Prime vs. Debridement (Surgical Standard of Care (SSOC)) for the Treatment of Osteochondral Lesion of the Knee Joint - OSTEOCONFIRM Study
Plain-language title
MaioRegen Prime implant versus surgical cleaning for deep knee cartilage and bone damageGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07332182, who can take part
Record updated
6 October 2026